Unsolved issues in clinical gene therapy for cardiovascular diseases include gene transfer efficiency and the requirement of a longer exposure time. We developed a novel mononegavirus vector, recombinant Sendai virus (SeV), and tested whether it can overcome the present hurdles. SeV showed dose-dependent and persistent gene expression in either proliferating or arrested cells, suggesting stability of RNA genome of the vector. An outstanding feature of the SeVmediated gene transfer was that even a brief exposure provided nearly peak gene expression in both culture cells and human veins ex vivo, as well as rabbit carotid arteries in vivo. Gene transfer to human great saphenous veins showed high efficacy in luminal and vasa vasoral endothelial cells and in adventitial fibroblasts via both intraluminal delivery and simple floating; however, only scattered cells were transfected in both neointima and media, regardless of the infusion pressure. Veins with a dissected neointima showed a clear transfection to medial cells, suggesting that the barrier in neointima reduces SeV-mediated gene transfer to tunica media, similar to the case with adenoviruses. Although the fibromuscular neointima is a common obstacle, these findings suggest that SeV may overcome other limitations of current vectors. SeV may be an important new vector in treating subjects with vascular disorders.
ince early reports indicating successful recombinant gene expression in the vessel wall in vivo (1, 2), gene therapy is a possible option to treat human vascular diseases. However, safety issues and efficacy have slowed the transition from preclinical animal studies to clinical trials (3) .
Recombinant adenovirus is commonly used for vascular gene transfer. Although its gene transfer is efficient in the vessel wall, this vector also has several unresolved issues. Although adenovirus vectors can efficiently transfect exogenous genes to endothelial cells (ECs) and adventitia in uninjured vessels of laboratory animals (4, 5) as well humans (6) , relatively low rates of adenovirus uptake into atherosclerotic lesions and the medial layer in rabbits (7) and humans (6) limit its efficacy in cytostatic gene therapy strategy. Moreover, adenovirus-mediated gene transfer requires a relatively long exposure time to reach maximum gene transfer efficiency, also common with other currently available vectors (7) , probably because a longer attachment with the coxsackievirus-adenovirus receptor (CAR)-mediated internalization of vector particles is required. This is a major obstacle for clinical application, because of time limitations regarding a halt in coronary flow during percutaneous transluminal coronary angioplasty.
We previously reported that the liposome coated with Sendai virus (SeV; also called hemagglutinating virus of Japan [HVJ] ) envelope proteins, namely HVJ-liposomes, achieve a relatively high gene transfection efficiency, of more than 80% in medial smooth muscle cells of rabbit carotid arteries in vivo (8) . An electron microscopic study showed permeation of vector particles into the entire medial layer, suggesting a relatively higher permeability into the vessel wall of medium-sized animals (unpublished data). Using this vector system, we did several studies, including in vivo induction of vessels with a pathology via overexpression of genes such as vascular endothelial growth factor and human cytomegalovirus immediate early gene (8, 9) as well as in vivo suppression of vascular proliferative diseases, using endothelial constitutive nitric oxide synthase gene (10) or wild-type p53 gene (11) . Our preliminary results with human saphenous veins and coronary arteries with a pathology, however, indicated that gene transduction and expression efficiency via this vector were not effective, similar to findings in published data on adenoviruses (7) . The results obtained with adenovirus and HVJ-liposomes suggest the presence of biological barriers in a human vessel wall with a pathology. Thus, now adventitial gene delivery, using secreting therapeutic genes or enzyme-producing secretory substrates, has been done as an alternative (12, 13) . An important aspect of SeV-based vectors via fusion activity is the requirement of a brief interaction between cells and vector particles. We reported that <10 min of interaction time was sufficient to reach maximal gene transfer efficiency (8) .
We have recently developed a reverse genetics technology to produce a novel gene transfer vector, namely recombinant SeV (14-19), which shows a high level of transgene expression in some cells in vitro (16, 17) . SeV can overcome some biological barriers both for adenoviruses and cationic lipids in the native airway epithelia, suggesting a possible application for gene therapy for subjects with cystic fibrosis. A brief vector interaction resulted in similar transfection activity to that of continuous perfusion in the mouse nose (18) .
In this study, we examined the transfection ability of SeV in vitro and in vivo, including transfection and gene expression efficiency, duration of gene expression, and effect of vector S exposure time, in consideration of clinical settings. Furthermore, we used great saphenous veins of patients undergoing surgical stripping operations to investigate the gene transfer potential and transfected cell species of SeV. We found several important features of SeV that suggest it is clinically feasible, because it does not have the same problems associated with current vascular gene transfer vectors.
MATERIALS AND METHODS

Construction and rescue of recombinant SeV vectors
Recombinant SeVs were constructed as described previously (14:19) . In brief, 18 bp of spacer sequence 5'-(G)-CGGCCGCAGATCTTCACG-3' with a NotI restriction site were inserted between the 5' nontranslated region and the initiation codon of the nucleoprotein (N)-gene. This cloned SeV genome also contains a self-cleaving ribozyme site from the antigenomic strand of hepatitis delta virus (14) . The entire cDNA coding luciferase (for SeV-luciferase) and Escherichia coli lacZ with or without a nuclear localizing signal (for SeV-NLS-lacZ and SeVlacZ, respectively) were amplified by polymerase chain reaction, using primers with a NotI site and new sets of SeV E and S signal sequence tags for an exogenous gene, and inserted into the NotI site of the cloned genome. The entire length of the template SeV genomes, including exogenous genes, was arranged in multiples of six nucleotides (so-called "rule of six"; 20). Template SeV genomes with an exogenous gene and plasmids encoding N-, P-, and L-proteins (plasmids pGEM-N, pGEM-P, and pGEM-L) were complexed with commercially available cationic lipids and then cotransfected with vaccinia virus vT7-3 into CV-1 or LLMCK cells (21) . Forty hours later, the cells were disrupted by three cycles of freezing and thawing and injected into the chorioallantoic cavity of 10-day-old embryonated chicken eggs. Subsequently, the virus was recovered and the vaccinia virus was eliminated by a second propagation in eggs. We determined virus titer by using chicken red blood cells (22) in hemagglutination assay, and viruses were kept frozen at -80°C until use.
Cells and in vitro gene transfer
Bovine aortic smooth muscle cells (BSMCs) were obtained from bovine aortic tissue, as previously described (8, 9, 11) . Human umbilical vein endothelial cells (HUVECs) were isolated in the usual manner, and 0-3 passage of HUVECs were used for experiments. COS7 cells, African green monkey kidney cells transformed with simian virus 40 large T antigen, and human embryonic kidney cells (HEK293) were obtained from American Type Culture Collection (Manassas, Va.). Cells were grown on plastic culture dishes in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). BSMCs from passages 6-8 were used in this study. In all experiments, gene transfer was carried out by adding various concentrations of vector solutions to the culture media, and each reporter gene assay was done 48 h after gene transfection.
Luciferase assay and luminescent β-galactosidase assay for culture cells
Forty-eight hours after transfection, cells were washed twice with phosphate-buffered saline (PBS: 137 mM NaCl, 3 mM KCl, 8 mM Na 2 HPO 4 , and 1 mM KH 2 PO 4 ; pH 7.2) and treated with 200 µl of 1× cell culture lysis reagent (Promega, Madison, Mass.). The lysate was transferred to 1.5-ml Eppendorf tubes, and debris was removed by centrifugation at 15,000 rpm. For luciferase assay, 20 µl of the supernatant were exposed to 100 µl of luciferase assay buffer (Promega), and the relative luciferase activity was measured using a luminometer (Model LB9507, EG&G Berthold, Bad Wildbad, Germany). For the luminescent β-galactosidase assay, 20 µl of the supernatant were exposed to 200 µl of β-galactosidase reaction buffer (Clontech, Inc., Palo Alto, Calif.), and the relative β-galactosidase activity was measured using a luminometer. Protein concentrations were measured by Bradford's method with a commercially available protein assay system (Bio-Rad, Hertfordshire, U.K.), and data were expressed as relative light units (RLU)/mg protein. Each experiment was repeated more than twice for representative results.
X-Gal histochemistry for culture cells
Forty-eight hours after transfection, cells were washed twice with PBS and fixed with 2% formaldehyde for 10 min. Cells were then washed twice with PBS containing 0.1% Triton-X, and X-Gal solution [0.2% 5-bromo-4-chloro-3-indolyl-β-D-galactosidase, 1 mmol/l K 4 Fe(CN) 6 , 3.3 mmol K 3 Fe(CN) 6 , 60 mmol/l Na 2 HPO 4 , and 40 mmol/l NaH 2 PO 4 ] was added to each well and the preparation left at room temperature for 1 h. The reaction was stopped by immersion of the preparation in PBS, and the preparation was examined under a phase-contrast microscope.
In vivo gene transfer to rabbit carotid arteries
Animal experiments were reviewed by the Committee of Ethics on Animal Experiments and of Recombinant DNA Experiments, Faculty of Medicine, Kyushu University, and were carried out under the "Guidelines for Animal Experiments," Faculty of Medicine, Kyushu University. The National Institutes of Health's "Principles of Laboratory Animal Care" and "Guide for the Care and Use of Laboratory Animals" were also followed.
Male Japanese white rabbits (2.5-3.5 kg body weight, Chearls River strain) purchased from KBT Oriental Co. Ltd.(Tosu, Saga, Japan) were used in this study. The following procedures were performed, much as previously described (8, 9, 11) . Under sufficient anesthesia, the right common carotid artery was exposed. After clamping, a 24-gauge plastic catheter was inserted through the external carotid artery. The luminal space of the isolated arterial segment was rinsed with 5 ml of balanced salt saline to clear blood from the vessels, and vector solution was instilled in the arterial space without positive pressure. The catheter was removed, the external carotid artery was ligated, and arterial circulation was restored.
Gene transfer to human saphenous veins and organ culture
Experiments were done using human tissues obtained under written agreement from patients and were approved and permitted by ethics committees. Fresh human great saphenous veins were obtained during screening for varicose veins of the lower extremities and were subjected at random to two different gene transfer procedures. Twenty veins (male, 6; female, 14; age range, 22-82; mean age, 57.4) were collected, and two were excluded because phlebitis was apparent. These veins were cut into multiple segments and used in two different ways.
In the first way, simple floating, 85 vein segments were used (56 for luciferase assay and 29 for X-Gal histochemistry). Each vein segment was washed four times with PBS and then three times with DMEM with 10% FBS to remove all blood. These veins were sectioned into rings 5-10 mm long and placed in the fresh medium containing various concentrations of vector solution. At appropriate time points, these veins were washed with culture media and each was placed in six-well plates for organ culture.
In the second way, intraluminal gene transfer, 71 vein segments were sectioned into pieces 3-4 cm long. A 24-gauge needle was inserted from the distal side of each segment and fixed with 2-0 silk. After clamping the proximal side of the segment with vascular forceps, ~2 ml of vector solution containing various concentrations of the virus were injected into the luminal space at 0 (without denudation, n=24), 150 (n=11), 300 (n=9), or 760 (n=5) mm Hg of continuous positive pressure (measured with a hemomanometer) and incubated for 10 min. For some sections, the endothelium was removed using a 4 Fr Fogarty catheter (0 mm Hg, n=7; 150, n=6; 300, n=9). After 48 h cultivation for organ culture, these venous segments were subjected to appropriate reporter gene assays.
X-Gal histochemistry for rabbit and human vessels
Forty-eight hours after gene transfer, vessel segments were washed with PBS and then fixed for 10 min with 2% formaldehyde containing 0.25% glutaraldehyde. Next, the segments were washed with PBS containing 0.1% Triton-X and were reacted for 3 h with the X-Gal solution on a reciprocal shaker. These X-Gal-stained segments were refixed with phosphate-buffered formaline and examined under a dissecting microscope. The vessels were sectioned at ~5-mm intervals, embedded in paraffin (one to six sections per tissue), and 3-mm-thick sections were stained with nuclear fast red or with hematoxylin-eosin for light microscopic examination. The number of evaluated tissue sections of human veins is listed in Table 1 .
Luciferase assay for human vessels
At each time point, vessel segments were washed with PBS and minced using scissors in 500 ml of 1× cell culture lysis buffer. We centrifuged lysate at 15,000 rpm for 5 min at 4°C, and used a luminometer to subject 20 ml of supernatants to luciferase assay, as described previously.
Antibodies and immunohistochemistry
Monoclonal antibodies used as primary antibodies in this study were CD34 (Dakopatts, Glostrip, Denmark) for ECs and HHF 35 (Enzo Co. Farmingdate, N.Y.) for vascular smooth muscle cells (VSMCs). For the immunohistochemical examination, we used the standard avidin-biotin complex method with minor modifications (23).
Statistical analyses
All values are expressed as the mean ± SD. The data were analysed using the Mann-Whitney Utest, and the null hypothesis was rejected at P < 0.05.
RESULTS
Dose-dependent transfection of SeV in vitro and ex vivo
Dose-dependent SeV-mediated gene transfer was assessed using the established cell lines COS7 and HEK 293, which are readily transfectable, and BSMCs and HUVECs at the logarithmic proliferating phase. We assessed the gene transduction rate to BSMCs by using SeV-NLS-lacZ (n=3 each, Fig. 1A ). X-Gal histochemistry demonstrated the dose-dependent frequency of blue cells, and more than 90% of BSMCs were positive at multiplicity of infectins (MOI)=100. Similar to COS7 and HEK293 cells, HUVECs showed 100% lacZ gene transduction efficiency at MOI=3 (data not shown). For quantitative analysis using SeV-luciferase, COS7 and HEK293 cells exhibited dose-dependent increases in luciferase expression, with a plateau reached at titers of more than 3 MOI (MOI=3) (data not shown). Under the same experimental conditions, BSMCs also showed dose-dependent increases in luciferase expression at MOI=100 (Fig. 1B,  left) . HUVEC cells were easier to transfect, and maximum transgene expression was reached at MOI=10 (Fig. 1B, middle) .
Next, we asked whether recombinant SeV could be used to transfect the human vessel wall of saphenous veins. Vein segments 5-10 mm long were put in the vector solution with various concentrations of SeV-luciferase for 1 h. They were then cultured in fresh medium immediately after washings with immersion medium (n=6, each), and luciferase activity was measured 48 h later (Fig. 1B, right) . The dose-dependent increase of luciferase activity was apparent, similar to data for BSMCs and HUVECs.
Time-dependent gene expression following SeV-mediated gene transfer in vitro
To obtain information regarding the time-dependent exogenous gene expression following SeVmediated gene transfer, we examined luciferase activity on BSMCs at different time points after treatment of MOI=10 of SeV-luc (n=6 at each time point). Significant luciferase activity was detected even at 1 h after gene transfer, and expression level logarithmically increased, in a timedependent manner (mock: 4.6±0.4×10 4 11 RLU/mg; 3 days: 3.7±0.2×1011 RLU/mg). Therefore, subsequent experiments were usually done 2 days after gene transfer.
Assessment of direct cytopathic effect of SeV-mediated gene transfer
Next, we addressed the effect of SeV-mediated gene transfer on cell proliferation to check its direct cytotoxicity for vascular cells, because SeV is known to induce severe cytopathic effect (CPE) in some cells, such as CV-1 cells (15) . We used a hemocytometer to directly determine cell numbers at each time point.
As shown in Figure 2A , the growth of BSMCs was not inhibited by SeV infection up to MOI=100; however, growth inhibition was apparent at MOI=1000 on day 8 (P<0.01) and showed frequent cellular morphological changes and detachment, suggesting CPE at highest MOI. In the case of HUVECs, however, similar frequency of CPE-like appearance was found at MOI=10, and SeV-NLS-lacZ-mediated growth inhibition was apparent and significant at this dose (Fig. 2B) . To assess whether these cells were dying, we continued to culture these cells, because trypan blue stain and flow cytometry analysis suggested no apparant evidence of cell death (data not shown). It is of interest that these detached cells started to attach the bottom of the flasks at about 3 wk after gene transfer, and these cells restarted to show similar growth activity to untreated cells in later passages (Fig. 2B) . At that time, almost all cells were positive for X-Gal staining (data not shown), suggesting that the CPE-like effect induced by SeV was transient. Similar findings were also noted in eight different established human cell lines tested (data not shown), thus SeV-mediated CPE seems to depend largely on cell species.
Time course of exogenous gene expression
Paramyxoviridae, including SeV, exhibit genome replication and express their genes in a cytoplasmic manner, thereby suggesting a stable reporter gene expression in daughter cells. However, a defective interfering genome or accumulation of spontaneous mutations may affect gene expression levels (24) . Thus, we assessed the time course of reporter gene expression following SeV-luc-mediated gene transfer by using either proliferating or arrested cells.
SeV-luc was infected to logarithmically proliferating BSMCs at titer of MOI=0.1, 1, and 10 in 75-mm 2 flasks. At each time point, three-quarters of cells were used for the luciferase assay, and the remaining on quarter was followed to the next passage. In BSMCs, a high level of luciferase gene expression persisted up to day 37 with these three doses, and BSMCs showed a relatively stable luciferase expression (Fig. 3A, n=3 for each dose).
We used arrested BSMCs to determine the time course of reporter gene expression. Cells were allowed to become confluent for more than 2 days to arrest the cell cycle. Flow cytometry analysis indicated that more than 95% of BSMCs were at the G1/G0 phase (data not shown). Arrested BSMCs were exposed to SeV-luc at titer of MOI=0.1, 1.0, and 10 for 1 h, and at each time point, cells were subjected to luciferase assay (n=6, Fig. 3B ). Exogenous gene expression was highest on day 2 (1.1±0.4×10
11 RLU/mg) and gradually decreased with time, and at 14 days luciferase activity was the lowest (2.1±0.8 ×10 10 RLU/mg). The luciferase activity then began to increase gradually until at least day 28. These findings suggest that the SeV-mediated gene expression persisted for more than 1 month at a relatively high level.
Effect of vector exposure time on SeV-mediated gene transfer to BSMCs and human saphenous veins
One of the major clinical limitations of available vectors is the requirement of a relatively long exposure to a vector. To address this limitation, we tested exposure time-dependent gene transfer efficiency, using growth-arrested BSMCs and human saphenous veins.
BSMCs were placed in six-well culture plates and allowed to become confluent for 2 days. SeVlacZ (MOI=10) was added to each well, and the medium was removed after 1, 2, 5, 10, 30, 60, and 180 min and after 24 and 48 h. The preparation was washed twice with fresh medium, and 2 ml of 10% FBS in DMEM were placed in each well. Luminescent β-galactosidase assay was done 48 h after this transfection.
In the case of SeV, β-galactosidase gene expression was not markedly affected by vector-cell interaction time (Fig. 4A) , and only a 1-min exposure was sufficient to express a similar level of luciferase activity that occurred with 48 h of exposure (n=6). We obtained similar findings for human saphenous veins (Fig. 4B) and for BSMCs transfected with SeV-luc (data not shown). Therefore, the vector-cell interaction time is not a serious limiting factor for SeV, in agreement with findings for airway epithelial cells (17) . In contrast, adenovirus encoding lacZ exhibited a vector incubation time-dependent increase (Fig. 4C) , as documented for adenovirus-mediated gene transfer (25) .
In vivo intraluminal gene transfer to rabbit carotid artery
To assess whether the important features of SeV-mediated gene transfer, including both short transfection process and persistent gene expression demonstrated in vitro, were also consistent in vivo, we performed intraluminal gene transfer to rabbit arteries. Two minutes of SeV-NLSlacZ incubation (including the loss of time for catheter removal) without any infusion pressure demonstrated sufficient and dose-dependent (107 and 108 pfu/ml, n=6 each) gene transfer on the luminal surface, indicating consistent brief transfection activity of SeV in vivo (Figs. 5A , 5B). Histological assessment indicated endothelium-specific transgene expression (Fig. 5C ), suggesting that an important feature of SeV-mediated vascular gene transfer such as a brief transfection process was also representative in vivo.
Gene transfer efficiency to human saphenous veins
To evaluate the cell species expressing transgene via SeV-mediated gene transfer in human vessels, we conducted ex vivo gene transfer by using great saphenous veins obtained from patients with varicose veins during stripping surgical operation. The advantages of using these vessels are the ability to obtain diseased human vessels with various degrees of fibromuscular neointima, to obtain large amount of vessels, and to avoid frequent bacterial contamination. Disadvantages are frequent loss of ECs with surgical procedures and considerable fibrosis in the venous wall with small numbers of medial cells.
We determined intraluminal gene transfer into human saphenous veins, under various infusion pressures. SeV-NLS-lacZ (2 ml; 5×108 pfu) was infused into a 3-to 4-cm cut vein at an infusion pressure of 0, 150, 300, or 760 mm Hg (n=6 each) for 10 min. Some vessels had been injured with a balloon catheter and in these vector solution was infused at the same pressure (n=6). Control vessels were infused with mock virus (n=6). We evaluated gene expression by X-Gal staining 48 h after gene transfer.
The viability of cells in veins was assessed by nuclear stain with hematoxylin (Table 1 ). In the 760 mm Hg of infusion pressure group (n=5), marked loss of CD34-positive ECs and HHF35-positive VSMCs was apparent in all sections; therefore, this group was omitted from following evaluations. Luminal ECs were not used because of severe surface damage. Mean cell numbers in all other conditions were not significantly different, and these groups were evaluated for XGal stain.
A gross observation of vessels exposed to SeV-NLS-lacZ at various infusion pressures revealed diffuse, frequent, and intense blue spots on the luminal surface and adventitia (Figs. 6A, 6B) , whereas vessels exposed to mock virus showed no blue spots (Fig. 6C) . Histological examination indicated that these positive cells were largely composed of ECs on the luminal surface and at the vasa vasorum and adventitial fibroblasts (Figs. 6D, 6E ). Cell identity was confirmed by subsequent immunohistochemistry with CD34 and HHF35 (data not shown).
In balloon-injured vessels, blue spots on the luminal surface were markedly decreased (Fig. 7A) , whereas the adventitia showed a frequency of staining similar to the uninjured vessels, including the vasa vasorum (Fig. 7B, arrows) . Histological examination confirmed that only scattered cells with blue nuclei were observed in vessels with a thin neointima (Fig. 7C, arrows) , whereas almost no blue cells, except for scattered capillary ECs, could be seen in vessels with a thick neointima (Figs. 7D, 7E , arrows). We suggest that these findings do not always imply low transduction efficiency to VSMCs, because relatively frequent medial cells were positive for XGal in some vessels with a neointimal tear (Figs. 7F, 7G, arrows) . These results suggest that the neointima, but not ECs, may be a significant barrier to SeV-mediated gene transfer to human vessels.
Histological sections subsequently subjected to immunohistochemistry were used to quantify the percentage of X-Gal-positive cells in the intima, media, and adventitia (Table 2) . SeV-mediated gene transfer efficiency of uninjured vessels was similar to that of simple floating samples, at any infusion pressure, whereas an increased number of gene transferred cells was observed in the neointima of injured vessels. In addition, an increase in X-Gal-positive cells was evident in both media and adventitia of veins with neointimal tears, supporting the histological data shown in Figures 7F and 7G . However, even in samples with tears, gene transfer efficiency was still low.
DISCUSSION
We have characterized vascular gene transfer by using recombinant SeV, a novel, highly efficient viral vector. Key aspects of this study are that brief exposure of the vessel wall to vector solution was sufficient for effective gene transfer in vitro and ex vivo, as well as in vivo, and that viral genome and exogenous gene expression were relatively stable in both proliferating and arrested cells for at least 1 month in vitro. These results are in clear contrast to reported findings with adenovirus vectors, commonly used in the field of vascular gene transfer studies. In addition, we demonstrated that several important advantages of adenoviral vectors, including high-level transgene expression and high transfection ability independent of the cell cycle, are common to recombinant SeV. However, this new vector also could not overcome the biological barrier of a thickened fibromuscular neointima, similar to adenoviruses (3-7). Considering these features of our vector, we attempted to establish appropriate vascular gene therapy in a clinical setting.
One of the outstanding features of recombinant SeV is the brief transfection process. This may be particularly advantageous for intraluminal gene transfer to arteries during percutaneous transluminal coronary angioplasty (PTCA) brief cut off of the blood flow for gene transduction.
Guzman et al. demonstrated that an adenovirus vector carrying lacZ could transfect up to 25% of VSMCs with a 5-min exposure and up to 80% with a 120-min exposure (25) , and this was also the case with BSMCs in this study (Fig. 4C) . Because this has been a practical issue for application to PTCA, SeV may be considered in the case of EC-targeted gene transfer. In fact, an in vivo study using rabbit carotid arteries also showed that a 2-min vector incubation time was enough to obtain sufficient transgene expression (Figs. 5A-C) .
Another important advantage of SeV is at least a 1-month genomic stability resulting in a persistent gene expression in vitro, even in proliferating cells. In arrested BSMCs, luciferase activity was transiently and mildly decreased, then almost recovered (Fig. 3) . Although the exact mechanism of such a time course is unclear, recovery of gene expression is not likely for the SeV vector to accumulate spontaneous mutations, but is due to transient cellular accumulation of defective interfering genome. Because recombinant SeV is a cytoplasmic transcription system, our data indicate that not only is exogenous gene expression relatively stable and inherited by daughter cells, but so is genome replication. One limitation of this study is that we did not assess immunogic/inflammatory issues, including induction of the host immune response in vivo, especially cytotoxic T-lymphocyte activation, which has been a major hurdle to limit the duration of exogenous gene expression via adenovirus-mediated gene transfer. It is still premature, we believe, to explain the possible immunologic consequences, thus we are now assessing these via extensive studies to clarify whether vector-specific or transfected cell-specific immunological response occurs with our novel vector.
The use of human saphenous veins in ex vivo studies showed that SeV-mediated gene transfer is a highly efficient method for use with either ECs or adventitial fibroblasts, but not so effective for VSMCs beneath the fibromuscular neointima. An increase in gene transfer to either neointima or medial layer was not observed at any pressure. In addition, a tear of the neointima accelerated medial gene transfer, suggesting that the neointima structure may be a major obstacle to SeV-mediated gene transfer to VSMCs, similar to the case with adenovirus (6, 7). These findings are similar to reports of Rekhter et al. who used human vessels (6) and Feldman et al. who used atherosclerotic arteries from rabbits (7) . Considering the relatively low rate of gene transfer to the medial layer under the neointima and extensive denudation of EC lining on vein grafts implanted into arterial circulation (26) , an alternative gene transfer strategy, such as adventitial gene delivery (12, 13) , should be considered for application of SeV to prevent post-PTCA or postgrafting restenosis.
In SeV vector system, exogenous gene expression is driven by self-RNA polymerase (L-protein) harmonized with cellular tubulin (27) and accerelated by host phosphoglycerate kinase (28) in a cytoplasmic manner, without the requirement of nuclear localization, which has been a major hurdle in the reduction of gene transfer. This also indicates that SeV does not interact with the host genome, suggesting a lack of theoretic risks, including carcinogenic ability. Also, SeV is pathogenic for rodents, causing pneumonia, but not so for humans. This finding is also supported by a previous report indicating no serious adverse effects in nonhuman primates via nasal administration of wild-type SeV (29) . Although extensive safety and toxicity studies should be carried out before clinical studies, these characteristics of SeV may suggest that it is feasible for use in human studies.
According to these important features of SeV-mediated vascular gene transfer, we should establish therapeutic strategies to treat clinical cardiovascular disease. The great advantage of using SeV is the ability to acheive highly efficient gene transfer to ECs during brief clamping time, suggesting its feasibility in catheter-based gene delivery applicable not only to peripheral arteries but also to coronary arteries. ECs seem to be an attractive target for local and continuous therapeutic protein secretion affecting peripheral organs, such as angiogenic factors or antiinflammatory molecules. Regarding restenosis therapy, preexisting atherosclerotic change or fibrocellular neointima are important barriers. In this regard, endothelial and adventitial gene delivery of secreting antiproliferative molecules (31, 32) or of enzymes stimulating antiproliferative substances (10, 12, 13) may be ideal candidates. When these biological barriers could be removed by vascular interventions, such as directional coronary atherectomy, cellular antiproliferative molecules, including p21waf-1/cip-1 and wild-type p53 (11), may be possible candidates. Further studies are called for to clarify that these molecules showing successful results in small animals can demonstrate similar effective properties in diseased large animals before clinical studies.
Overall, although the reservation regarding the low rate of vector uptake to neointima and media has been common to currently available vascular gene transfer vectors, recombinant SeV seems to overcome several other important issues in the field of vascular gene delivery. We conclude that SeV vector could be an important alternative to gene therapy for treating vascular disorders. Table 1   Table 2 Fig. 1 In 6-well plates,105 cells were placed in each well, and SeV-luciferase at multiplicity of infections (MOI) = 0.1, 1, 10, 100 as well as wild-type SeV at MOI = 100 were added (n=6 for each). Forty-eight hours later, cells were subjected to luciferase assay. Data are expressed as mean ± SD, and the value of each well standardized by protein concentration. Human saphenous veins: Veins (5-10 mm long) were washed and placed in either vector solutions containing SeVluciferase at 107, 108, or 109 plaque forming unit/ml, or without virus (n=6). Forty-eight hours later, veins were subjected to luciferase assay. Data are expressed as mean ± SD, and the value of each well standardized by protein concentration. , and just before confulency, three-quarters of the cells were subjected to luciferase assay. The remaining cells were passaged repeatedly. Each luciferase activity was standardized by protein concentration. Mean value at each MOI was plotted, and SD was expressed as error bars These experiments were done in triplicate, and data contain all three sets. Note the log scale. (B) Bar graph indicates time course of exogenous gene expression, suggesting genome stability in the growth-arrested BSMCs. Growth of BSMCs was arrested at confulency and then left for 2 days. Cells were exposed to SeV-luciferase at MOI=10 for 1 h and subjected to luciferase assay at each time point (n=6). Data were standardized by protein concentration, and the mean value and the SD were expressed as bar graphs and error bars, respectively. Note the log scale. . BSMCs were exposed to the SeV-lacZ at multiplicity of infections (MOI) = 10 for each duration and were washed twice with fresh medium (n=6 for each). Forty-eight hours later, cells were subjected to luminescent β-galactosidase assay. Data are expressed as mean ± SD, and each dot indicates the value of each well standardized by protein concentration. Note the log scale. (B) Effect of vector exposure time on SeV-mediated gene transfer on human saphenous veins. Human great saphenous veins (5-10 mm long) with a pathology were exposed to the SeV-luciferase at MOI = 10 for each duration (1, 2, 5, 10, 30, and 60 min or 3 and 6 h), washed four times with fresh medium, and placed on culture plates (n=6 for each). Forty-eight hours later, veins were subjected to luciferase assay. Data are expressed as mean ± SD, and each dot indicates the value of each well standardized by protein concentration. Note the log scale. (C) Effect of vector exposure time on recombinant adenovirus-mediated gene transfer on BSMCs. BSMCs were exposed to the AdexCA-lacZ at MOI=10 for each duration and washed twice with immerse fresh medium (n=6 for each). Fortyeight hours later, cells were subjected to luminescent β-galactosidase assay. Vector exposure time-dependent increase of transgene expression was apparent. Data were expressed as mean ± SD, and each dot indicates the value of each well standardized by protein concentration. Note the log scale. 
